The warfarin embryopathy is a well-defined complex of fetal anomalies
generally accepted to result from first trimester exposure. Optic atro
phy and dilation of the cerebral ventricles associated with blindness,
microcephaly, and mental retardation have been reported following sec
ond and third trimester exposure. In contrast to the consistent clinic
al features observed in the warfarin embryopathy, the CNS effects seen
in fetuses exposed in the later trimesters share little in terms of s
pecific lesion or long-term clinical outcome. A case of schizencephaly
in a coumadin-exposed fetus is presented. This report offers supporti
ve evidence that the CNS sequellae of this agent are the result of vas
cular accident and hemorrhage, not a direct effect on CNS morphogenesi
s. The molecular basis for the adverse effects of warfarin derivatives
on the fetus are reviewed. Warfarin derivatives exert both their embr
yopathic and their fetopathic effects via pharmacologic action: inhibi
tion of gamma carboxylation of osteocalcin and a similar carboxylation
of the vitamin K dependent clotting factors. Therefore, we believe th
at warfarin exposure in the second or third trimesters of pregnancy is
equally dangerous to the fetus as that in the first. Heparin may be a
superior alternative to warfarin for the prevention of thromboembolic
disease in pregnant women with cardiac value prostheses.